A final appraisal determination (FAD) for the above appraisal was scheduled to be released for appeal this week. The company that markets atezolizumab, Roche Products, has requested that NICE consider a new value proposition for this population. NICE has agreed to this and therefore the FAD release has been suspended. A further update on the appraisal and associated timelines will follow in due course.